跳到正文
DaisukeKotani· @DaisukeKotani · X·· 4 天前评分60
正文 · 原文

#ESMO26 | 2894P Retrospective study of 1L Tx for ESCC with supraclavicular lymph node metastasis Chemo + ICI (CI) vs CRT (CCRT) vs Chemo + ICI followed by RT (CIRT) ▪️3y-OS: 52.1% vs 70.8% vs 69.8% ▪️Superior PFS in CIRT vs CI (adjusted HR 0.73), OS (HR 0.48) ▪️Superior PFS in CIRT vs CCRT (HR 0.67) 👉Clinically meaningful analysis, although potential selection and immortal time biases should be considered, as patients with early progression on chemo + ICI may not have entered the CIRT group. @myESMO @OncoAlert

热度 13 · 7 赞 · 0 回复 · 6 转发

来源:DaisukeKotani · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org